Please login to the form below

Not currently logged in
Email:
Password:

relugolix

This page shows the latest relugolix news and features for those working in and with pharma, biotech and healthcare.

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

FDA approves Myovant’s oral pill Orgovyx for prostate cancer

Orgovyx (relugolix), which will become available for advanced prostate cancer patients in the US, offers a new option that enables at-home administration. ... Secondary endpoints from the study showed that relugolix was better than Lupron at suppressing

Latest news

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....